W
Wolfgang Koenig
Researcher at Technische Universität München
Publications - 130
Citations - 14704
Wolfgang Koenig is an academic researcher from Technische Universität München. The author has contributed to research in topics: Population & Coronary artery disease. The author has an hindex of 37, co-authored 130 publications receiving 10052 citations. Previous affiliations of Wolfgang Koenig include University of Ulm & McGill University.
Papers
More filters
Proceedings ArticleDOI
Longitudinal changes of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) and total mortality in elderly people: the ActiFE Study
Journal ArticleDOI
Clinical Chemistry's Special Issue on Men's Health
Jason Y. Park,Madeline B. Deutsch,Wolfgang Koenig,Hans Lilja,Elizabeth A. Platz,Elizabeth A. Platz +5 more
TL;DR: In this special edition, it is attempted to examine men's health not as a monolithic topic, but rather an examination of health related to anatomy, gender, nationality, and various cultural practices.
Journal ArticleDOI
Response to Drs. Rasmussen and Pareek regarding our paper in Int. J. Cardiol. 2018; 250: 247-252: Hs-cTroponins for the prediction of recurrent cardiovascular events in patients with established CHD - A comparative analysis from the KAROLA study.
Journal ArticleDOI
Dataset of the associations of aldosterone to renin ratio with MR-proANP and MR-proADM.
Cornelia Then,Marietta Rottenkolber,Andreas Lechner,Christa Meisinger,Margit Heier,Wolfgang Koenig,Annette Peters,Wolfgang Rathmann,Martin Bidlingmaier,Martin Reincke,Jochen Seissler +10 more
TL;DR: The association of the aldosterone to renin ratio with midregional-pro atrial natriuretic peptide (MR-proANP) and midregual-pro adrenomedullin ( MR-proADM) in 1261 participants from the KORA F4 cohort is described.
Journal ArticleDOI
Interleukin-17 in atherosclerosis: Still a long road ahead
TL;DR: Strict follow-up of patients with psoriasis currently undergoing IL-17 inhibition with the three available inhibitors with theThree available inhibitors is necessary, regarding atherosclerotic plaque progression, inflammatory activity and cardiovascular events.